From our Expert Voices conversation on drug pricing.

The recent FDA approval of CAR T-cell therapy is a major milestone in the longstanding effort to cure childhood cancer, once almost uniformly fatal.

The problem: Today childhood leukemia is treatable in most cases and 80% of children survive longer than five years. Unfortunately, early exposure to radiation and chemotherapy can have devastating long-term health impacts for childhood cancer survivors. Up to a third of long-term survivors will suffer from at least one life-threatening or debilitating medical problem caused by their "curative" treatment, which can include secondary cancers, severe cardiovascular disease, infertility, and endocrine disorders. Thus, many are trading one difficult disease for a lifetime battling numerous health problems.

Why it matters: Because they selectively target tumor cells and spare normal cells, new therapies like CAR-T presumably will result in less damage to normal tissues and cause fewer long-term health problems. They offer incredible hope to a new generation of childhood cancer patients that they can not only be cured, but can look forward to a productive life without additional health burdens.

The bottom line: While the upfront cost of these new therapies are high, any consideration of value should take into account the health care savings generated by an overall healthier and productive population of childhood cancer survivors.

Other voices in the conversation:

Go deeper

Updated 12 mins ago - World

At least 50 killed, 3,000 injured after massive explosion rocks Beirut

Photo: Anwar Amro/AFP via Getty Images

A major explosion has slammed central Beirut, Lebanon, damaging buildings as far as several miles away and injuring scores of people.

Driving the news: The cause of the explosion is unknown. Lebanon's health minister said in televised remarks that more than 50 people have been killed and over 3,000 injured.

48 mins ago - Podcasts

The debate over COVID-19 liability protections

Stimulus talks continue to move slowly, with Democrats and Republicans unable to agree on whether or not to include coronavirus-related liability protections for businesses, health facilities and schools.

Axios Re:Cap digs into the debate, which could reset the cost-benefit analysis for businesses thinking about reopening and employees thinking about returning.

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 3 p.m. ET: 18,364,694 — Total deaths: 695,848 — Total recoveries — 10,965,634Map.
  2. U.S.: Total confirmed cases as of 3 p.m. ET: 4,742,277 — Total deaths: 156,133 — Total recoveries: 1,513,446 — Total tests: 57,543,852Map.
  3. States: New York City health commissioner resigns in protest of De Blasio's coronavirus response — New York ER doctor on pandemic advice: "We know what works"
  4. Public health: 59% of Americans support nationwide 2-week stay-at-home order in NPR poll Atrium Health CEO says "virtual hospital" has treated 13,000 COVID patients.
  5. Politics: Republicans push to expand small business loan program Trump tells "Axios on HBO" that pandemic is "under control," despite surges in infections.
  6. Sports: Indy 500 to be held without fansRafael Nadal opts out of U.S. Open.